

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12P 21/04	A1	(11) International Publication Number: WO 95/27074 (43) International Publication Date: 12 October 1995 (12.10.95)
(21) International Application Number: PCT/US95/03948 (22) International Filing Date: 31 March 1995 (31.03.95) (30) Priority Data: 222,157 4 April 1994 (04.04.94) US (71) Applicant: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors: BALKOVEC, James, M.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BOUFFARD, Frances, Aileen; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BLACK, Regina, M.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Agent: MERCK & CO., INC.; Patent Dept., 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i>	

(54) Title: **ANTIFUNGAL AND ANTI-PNEUMOCYSTIS COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF USE**

(57) Abstract

Compounds represented by formula (I) (SEQ ID NO. 1) are disclosed, as well as pharmaceutically acceptable salts and hydrates thereof. R^1 represents C_9 to C_{19} alkyl, C_9 to C_{19} alkenyl, an aryl group which includes phenyl, biphenyl, naphthyl and terphenyl, or a C_1 to C_{12} alkyl, alkylamino, dialkylamino or alkoxyaryl group. R^1 , R^2 and R^4 independently represent H or -OH. R^3 represents H, -OH, $-O(CH_2)_nNR^VR^VI$, where R^V and R^VI independently represent H or C_{1-4} alkyl, or $-O(CH_2)_nNR^VR^VI R^{VII}+Y-$, wherein R^V and R^VI are as defined above, R^{VII} represents H or C_{1-4} alkyl, n is an integer of from 2-6 inclusive, and Y represents a counterion. R^5 represents H, -CH₃ or -OH; R^6 represents H or -CH₃; R^7 represents H, -CH₃, $-CH_2C(=O)NH_2$, $-(CH_2)_2NR^VR^VI$ or $-(CH_2)_2NR^VR^VI R^{VII}+Y-$ with n , R^V , R^VI , R^{VII} and Y as defined above; and R^8 represents -Cl, -Br, -I, -NO₂, -N₃, $-(CH_2)_0-4NH_2$, $-(CH_2)_0-4NH(C_{1-4}alkyl)$, $-(CH_2)_0-4N(C_{1-4}alkyl)_2$, $-(CH_2)_0-3CH(=NOH)$, $-NHC(=O)(CH_2)_{1-6}NH_2$ or $-NHC(=O)(CH_2)_{1-6}NHC(=NH)(CH_2)_0-3H$. Pharmaceutical compositions and methods of use are also disclosed.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLE OF THE INVENTION

ANTIFUNGAL AND ANTI-PNEUMOCYSTIS COMPOUNDS,
COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND
METHODS OF USE

5

BACKGROUND OF THE INVENTION

The present invention relates to antifungal and anti-Pneumocystis compounds with a substituent group at the 3' position of the homotyrosine peptide.

10

There presently exists a need for new antifungal and anti-Pneumocystis compounds due to an increase in the number of isolates which are resistant to conventional agents. Also, conventional agents show somewhat high levels of toxicity, which limits the usefulness of these agents. Lastly, the incidence of *Pneumocystis carinii* pneumonia is increasing, particularly in view of the high incidence of immunocompromised patients, e.g., suffering with AIDS.

15

SUMMARY OF THE INVENTION


Compounds represented by the formula I (SEQ ID NO. 1) are disclosed:

20

25

30

- 2 -



as well as pharmaceutically acceptable salts and hydrates thereof.

R^I represents C9 to C19 alkyl, C9 to C19 alkenyl, an aryl group which is selected from the group consisting of phenyl, biphenyl, naphthyl and terphenyl, or a C1 to C12 alkyl, alkylamino, dialkylamino or alkoxyaryl group.

R^1 , R^2 and R^4 independently represent H or -OH.

R^3 represents H, -OH, $-O(CH_2)_nNR^VR^VI$, where R^V and R^VI independently represent H or C1-4 alkyl, or $-O(CH_2)_nNR^VR^VI R^{VII}+Y^-$, wherein R^V and R^VI are as defined above.

R^{VII} represents H or C1-4 alkyl, n is an integer of from 2-6 inclusive, and Y represents a counterion.

R^5 represents H, -CH₃ or -OH;

R^6 represents H or -CH₃;

R^7 represents H, -CH₃, $-CH_2C(=O)NH_2$, $-(CH_2)_2NR^VR^VI$ or $-(CH_2)_2NR^VR^VI R^{VII}+Y^-$ with R^V , R^VI , R^{VII} and Y as defined above;

and R^8 represents -Cl, -Br, -I, -NO₂, -N₃, $-(CH_2)_{0-4}NR^VR^VI$ with R^V and R^VI as previously defined, $-(CH_2)_{0-3}CH(=NOH)$, $-NHC(=O)(CH_2)_{1-6}NH_2$ or $-NHC(=O)(CH_2)_{1-6}NHC(=NH)(CH_2)_{0-3}H$.

- 3 -

Pharmaceutical compositions are also included, which are comprised of a compound represented by formula I in combination with a pharmaceutically acceptable carrier.

5 A method of treating a fungal infection is also included, which is comprised of administering to a mammalian patient in need of such treatment a compound represented by formula I in an amount effective to treat the fungal infection.

10 A method of treating a *Pneumocystis carinii* infection is also included, which is comprised of administering to a mammalian patient in need of such treatment a compound represented by formula I in an amount effective to treat the *Pneumocystis carinii* infection.

15 A method of preventing a *Pneumocystis carinii* infection in an immunocompromised mammalian patient in need of such treatment is also included, which is comprised of administering to said patient an effective amount of a compound represented by formula I to prevent an occurrence of *Pneumocystis* infection.

DETAILED DESCRIPTION OF THE INVENTION

20 The invention is described herein in detail using the terms defined below unless otherwise specified.

The term "alkyl" refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 30 carbon atoms unless otherwise defined. It may be straight, branched or cyclic. Preferred alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, cyclopentyl and cyclohexyl. When substituted, alkyl groups may be substituted with up to three substituent groups at any available point of attachment. When the alkyl group is said to be substituted with an alkyl group, this is used interchangeably with "branched alkyl group". When the alkyl group is substituted with a cycloalkyl group, the cycloalkyl group may be at any available point of attachment. The alkyl portion of "alkoxy" is also defined as above.

30 Cycloalkyl is a specie of alkyl containing from 3 to 15 carbon atoms, without alternating or resonating double bonds

- 4 -

between carbon atoms. It may contain from 1 to 4 rings which are fused. The preferred cycloalkyl groups are cyclopentyl and cyclohexyl.

5 Aryl refers to aromatic rings e.g., phenyl, substituted phenyl and the like, as well as ring systems which are fused, e.g., naphthyl, phenanthrenyl and the like. Aryl groups may also contain one or more aryl groups singly bonded to each other. Aryl groups thus contain at least one ring having at least 6 atoms, with up to five such rings being present, containing up to 30 carbon atoms therein,
10 with alternating (resonating) double bonds between adjacent carbon atoms. The preferred aryl groups are phenyl, biphenyl, naphthyl and terphenyl. When specified as such, aryl groups may likewise be substituted. Preferred substituted aryls include phenyl and naphthyl substituted with one or two such groups.

15 The term "halogen" refers to F, Cl, Br or I.

The term "heteroatom" means O, S or N, selected on an independent basis.


Aralkyl is a specie of substituted alkyl, containing up to three aryl groups substituted on a straight, branched or cycloalkyl
20 group. The most preferred aralkyl group is benzyl ($-\text{CH}_2\text{C}_6\text{H}_5$).

Alkoxy refers to C_1 - C_4 alkyl-O-, with the alkyl group optionally substituted.


The term "alkoxyaryl" thus refers to a C_{1-12} alkyl-O-group, except where it is specified that the alkyl portion thereof is a
25 different number of carbon atoms, e.g., C_9 -20 alkyl. The alkoxy portion thereof is substituted on an aryl group, e.g., a phenyl ring, at any available point of attachment. Likewise, the substituent groups "alkylamino" and "dialkylamino" refer to substituent groups having one or two C_{1-12} alkyl groups attached to a nitrogen atom, which is
30 in turn substituted onto the aryl group which is selected from phenyl, biphenyl, naphthyl and terphenyl. When the aryl group is substituted with an alkyl radical, said alkyl radical is a C_{1-12} group.

The term "echinocandin B nucleus" (SEQ ID NO. 2) refers to the structure:

- 5 -



where X represents NH_2 . In echinocandin B, X represents



- 20 This lipophilic side chain can be removed enzymatically or through fermentative means. The nucleus typically is missing the side chain referred to above, and this is replaced with an alternate side chain in accordance with the chemical synthesis described herein.

When an alkyl, cycloalkyl or aryl group is termed "substituted", this means that from one to three substituent groups is present, at any available point of attachment. Substituent groups include the following: C1-6 alkyl; halogen, as defined above; hydroxyl; amino; C1-6 alkylamino; C1-6 dialkylamino or C1-6 alkoxy.

Where a particular substituent group is shown with a bond attached, e.g., when R^1 is equal to $-\text{OCH}_2\text{CH}_2\text{NH}_2$ the bond is shown drawn to the substituent group for purposes of identifying the point of attachment, and is not to be taken as an indication with the generic structure that a double bond is intended. Double bonds are plainly shown, such as in the imino group ($=\text{NH}$) attached to a carbon atom via a double bond when R^8 represents

30

- 6 -


-NHC(=O)(CH₂)₁₋₆NHC(=NH)(CH₂)₀₋₃H .

A subset of compounds which are addressed herein is represented by formula I-a which (SEQ ID NO. 3) has the following formula:

5

10

15



20

$R^8 = -Cl, -I, -NO_2, -N_3, -NH_2, -NHC(=O)CH_2NH_2,$
 $-NHC(=O)CH_2CH_2NH_2, -NHC(=O)CH_2CH_2NH(C=NH)CH_3$


25

It is noted that the peptide at position six of the cyclic hexapeptide is a 3-hydroxyproline residue and the peptide at position one is a 4,5-dihydroxyornithine residue.

Another subset of compounds which fall within the present invention is represented by the formula I-b.

30

- 7 -




These compounds are characterized as including a threonine at position five, a 3-hydroxy-4-methyl proline residue at position six, and a 4-hydroxy ornithine at position one.

Another subset of compounds of the present invention is represented by formula 1-c set forth below.

25

30

- 8 -





R⁸ = I, NO₂, NH₂, -N₃, -CH₂CH(=NOH), -CH₂CH₂NH₂

20 Another subset of compounds of the present invention is represented by formula 1-d set forth below.

25



30

- 9 -



Another subset of compounds of the present invention is
represented by formula 1-e set forth below.

- 10 -



20 The compounds of formula I and of all subsets thereof are substituted ortho to the homotyrosine phenol group, with the variable R^8 . R^8 is a member selected from the group consisting of: -Cl, -Br, -I, -NO₂, -(CH₂)₀₋₄NR^VR^{VI} with R^V and R^{VI} as previously defined, -N₃, -(CH₂)₀₋₃CH(=NOH), -NHC(=O)(CH₂)₁₋₆NH₂ or -NHC(=O)(CH₂)₁₋₆NHC(=NH)(CH₂)₀₋₃H.

25 In the case where a substituent group pertains to a basic moiety such as amino, alkylamino or imino, where an acid addition salt is possible (e.g. -NH₃⁺Y⁻), Y represents a counterion. Thus, Y⁻ can represent any of the negatively charged species set forth below.

30 Y⁻ may be a negatively charged counterion selected from the group: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bromide, butyrate, citrate, camphorate, camphorsulfonate, chloride, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, lactate,

- 11 -

maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, trifluoroacetate (TFA), tosylate and undecanoate.

5 The compounds of the present invention are useful per se and in their pharmaceutically acceptable salt and hydrate forms in the treatment of fungal and *Pneumocystis* infections in animal and human subjects. The term "pharmaceutically acceptable salt and hydrate," refers to those salts and hydrated forms of the compounds
10 of the present invention which would be apparent to the pharmaceutical chemist. i.e., those which are substantially non-toxic and which may favorably effect palatability, absorption, distribution, metabolism and excretion. Other factors, more practical in nature, which are also important in the selection, are cost of the raw
15 materials, ease of crystallization, yield, stability, hygroscopicity, and flowability of the resulting bulk drug. Conveniently, pharmaceutical compositions may be prepared from the active ingredients in combination with pharmaceutically acceptable carriers. Thus, the present invention is concerned with pharmaceutical compositions and
20 methods of treating infections utilizing as an active ingredient the novel cyclic peptide compounds.

 The pharmaceutically acceptable salts referred to above also includes substantially non-toxic acid addition salts. The Formula I compounds can be used in the form of salts derived from inorganic
25 or organic acids. Included among such salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate,
30 heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate.

- 12 -

The compounds of the present invention are valuable antifungal agents, which are active against various fungal organisms, and accordingly will likely find utility in human and veterinary medicine. The compounds of the invention are not limited to utility
5 as medicaments; they may be used in all manner of industry, for example: additives to animal feed, preservation of food, disinfectants, and in other industrial systems where control of fungal growth is desired. For example, they may be employed in
10 compositions in concentrations ranging from about 0.01 to about 100 parts of antifungal agent per million parts of solution in order to destroy or inhibit the growth of harmful fungi on medical and dental equipment and as fungicides in industrial applications, for example in water based paints and in the white water of paper mills to inhibit the growth of harmful fungi.

15 In vitro antifungal activity which is determined in accordance with the protocol set forth below is predictive of in vivo activity, when the compounds are administered to a mammal infected with a susceptible fungal organism.

The compounds of the present invention are active against
20 many fungi and particularly against *Candida*, *Aspergillus* and *Cryptococcus* species. The antifungal properties may be illustrated with the minimum fungicidal concentration (MFC) determination against certain *Candida* and *Cryptococcus* organisms in a microbroth dilution assay carried out in a Yeast Nitrogen Base (Difco) medium with
25 1 percent dextrose (YNBD).

In a representative assay, a compound of the invention is solubilized in 100 percent dimethyl sulfoxide (DMSO) at an initial concentration of 5 mg/ml. Once dissolved, the drug stock is brought to a concentration of 512 mcg/ml by dilution in water such that the final
30 DMSO concentration is about 10 percent. The solution is dispensed via a multichannel pipette into the first column of a 96-well plate (each well containing 0.075 ml of YNBD), resulting in a drug concentration of 256 mcg/ml. Compounds in the first column are diluted 2-fold across the

- 13 -

rows yielding final drug concentrations ranging from 256 mcg/ml to 0.12 mcg/ml.

Four hour broth cultures of organisms to be tested are adjusted using a spectrophotometer at 600 nm to equal a 0.5 McFarland Standard. This suspension is diluted 1:100 in YNBD to yield a cell concentration of $1-5 \times 10^4$ colony forming units (CFU) per ml.

Aliquots of the suspension (0.075 ml) are inoculated into each well of the microtiter plate resulting in a final cell inoculum of $5-25 \times 10^3$ CFU/ml and final drug concentrations ranging from 128 mcg/ml to 0.06 mcg/ml. Each assay includes one row for drug-free control wells and one row for cell-free control wells.

After 24 hours of incubation, the microtiter plates are gently shaken on a shaker to resuspend the cells. The MIC-2000 inoculator is used to transfer a 1.5 microliter sample from each well of the 96-well microtiter plate to a single reservoir inoculum plate containing Sabouraud dextrose agar (SDA). The inoculated SDA plates are incubated for 24 hours at 35°C.

The following data pertains to compounds of formula I-a with R⁸ defined below:

20	<u>R⁸</u>	MFC (mcg/mL) (<i>C. albicans</i> MY1055)
	Cl	1
	NO ₂	8
25	NH ₂	2
	N ₃	0.50
	NHC(=O)CH ₂ NH ₂	0.25
	NHC(=O)CH ₂ CH ₂ NH ₂	0.25
30	NHC(=O)CH ₂ CH ₂ NHC(=NH)CH ₃	0.25

- 14 -

The following data pertains to compounds of formula I-b with R⁸ defined below:

	<u>R⁸</u>	MFC (mcg/mL) <u>(C. albicans MY1055)</u>
5		
	NH ₂	1
	NO ₂	8

The following data pertains to compounds of formula I-c with R⁸ defined below:

	<u>R⁸</u>	MFC (mcg/mL) <u>(C. albicans MY1055)</u>
15	I	0.5
	NO ₂	2
	NH ₂	2
	N ₃	4
	CH ₂ CH(=NOH)	0.5

The following data pertains to compounds of formula I-d with R⁸ defined below:

	<u>R⁸</u>	MFC (mcg/mL) <u>(C. albicans MY1055)</u>
25	-NHC(=O)CH ₂ NH ₂	0.5

The following data pertains to compounds of formula I-e with R⁸ defined below:

	<u>R⁸</u>	MFC (mcg/mL) <u>(C. albicans MY1055)</u>
30		
	NH ₂	0.25
	N ₃	0.25

- 15 -

The activity of the compounds of the invention can also be demonstrated through an *in vivo* assay, as follows:

Growth from an overnight SDA culture of *Candida albicans* MY 1055 is suspended in sterile saline and the cell
 5 concentration determined by hemocytometer count and the cell suspension adjusted to 3.75×10^5 cells/ml. 0.2 ml of this suspension is administered I.V. in the tail vein of mice so that the final inoculum is 7.5×10^4 cells/mouse. The assay is then carried out by administering aqueous solutions of the compounds at various concentrations
 10 intraperitoneally (I.P.) twice daily (b.i.d.) for four consecutive days to 18-20 gram female DBA/2 mice, which previously had been infected with *Candida albicans* in the manner described above. Distilled water is administered I.P. to *C. albicans* challenged mice as controls. After seven days, the mice are sacrificed by carbon dioxide gas, paired
 15 kidneys are removed aseptically and placed in sterile polyethylene bags containing 5 mls of sterile saline. The kidneys are homogenized in the bags, serially diluted in sterile saline and aliquots spread on the surface of SDA plates. The plates are incubated at 35°C for 48 hours and yeast colonies are enumerated for determination of colony forming units per
 20 gram of kidney tissue.

Representative activities are listed below. The following data pertains to compounds of formula I-a with R⁸ defined below:

25	<u>R⁸</u>	<u>ED₉₉ (mg/kg)</u>
	-NH ₂	3.0
	-NHC(=O)CH ₂ CH ₂ NH ₂	<0.78

30 The compounds of the present invention may also be used to inhibit or alleviate *Pneumocystis carinii* infections in immunocompromised patients. *Pneumocystis carinii* may become opportunistic in mammals which are immunocompromised, such as in AIDS patients. The efficacy of the compounds for therapeutic or anti-

- 16 -

infective purposes may be demonstrated in studies on immunosuppressed rats.

In a representative study, Sprague-Dawley rats (weighing approximately 250 grams) are immunosuppressed with dexamethasone in the drinking water (2.0 mg/L) and maintained on a low protein diet for seven weeks to induce the development of *Pneumocystis pneumonia* from a latent infection. Before drug treatment, two rats can be sacrificed to confirm the presence of *Pneumocystis carinii pneumonia* (PCP).

Five rats (weighing approximately 150 grams) are injected twice daily for four days subcutaneously (sc) with a compound of the invention in 0.25 ml of vehicle (water). A vehicle control is also carried out. All animals are continued on dexamethasone in the drinking water and a low protein diet during the treatment period. At the completion of the treatment, all animals are sacrificed, the lungs are removed and processed, and the extent of disease determined by microscopic analysis of stained slides. An ED90 is thus obtained where at least 90% of the cysts present in the control animals are inhibited in the treated animals.

Representative activities are listed below. The following data pertains to compounds of formula I-a with R⁸ defined below:

	<u>R⁸</u>	<u>ED₉₀ (mg/kg)</u>
25	-NH ₂	0.075
	-NHC(=O)CH ₂ CH ₂ NH ₂	0.075

The following data pertains to compound of formula I-d with R⁸ defined below:

	<u>R⁸</u>	<u>ED₉₀ (mg/kg)</u>
30	-NHC(=O)CH ₂ NH ₂	0.019

- 17 -

With respect to *Pneumocystis*, the compounds of the invention can thus be used to treat an infection which has been diagnosed or the compound can be used in those mammalian patients who are immunocompromised and predisposed to developing a
5 *Pneumocystis* infection, to prevent the organism from becoming pathogenic and causing an infection. As used herein, both treatment modalities are included in the invention.

The compounds of this invention may be used in a variety of pharmaceutical preparations. The pharmaceutical
10 composition is comprised of a compound of formula I in combination with a pharmaceutically acceptable carrier.

The compound may be employed in solid, powder or crystalline form, in liquid solution, or in suspension. They may be administered by a variety of means; those of principal interest
15 include: topically, orally, parenterally by injection (intravenously or intramuscularly) and for purposes of treating *Pneumocystis* pneumonia, via inhalation as a powder or liquid.

Compositions for injection, one preferred route of delivery, may be prepared in unit dosage form in ampoules, or in
20 multidose containers. The injectable compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain various formulating agents. Alternatively, the active ingredient may be in powder (lyophilized or non-lyophilized) form for reconstitution at the time of delivery with a
25 suitable vehicle, such as sterile water.

Topical applications are also preferred for the treatment of candidiasis, and may be formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints, or powders.

Compositions administered orally may take such forms
30 as tablets, capsules, oral suspensions and oral solutions. The oral compositions may utilize conventional formulating agents, and may include sustained release properties as well as rapid delivery forms.

The dosage to be administered depends to a large extent upon the condition and size of the subject being treated, the route and

- 18 -

frequency of administration, the sensitivity of the pathogen to the particular compound selected, the virulence of the infection and other factors. Such matters, however, are left to the routine discretion of the physician according to principles of treatment well
5 known in the medical arts. Another factor influencing the precise dosage regimen, apart from the nature of the infection and peculiar identity of the individual being treated, is the molecular weight of the compound.

10 The compositions for human use per unit dosage, whether liquid or solid, may contain from about 0.01% to as high as about 99% of active material, the preferred range being from about 10-60%. The composition will generally contain from about 0.1 mg to about 2.0 g of the active ingredient; however, in general, it is
15 preferable to employ a dosage amount in the range of from about 1 mg to 500 mg.

In parenteral administration, the unit dosage will typically include the pure compound in sterile water solution or in the form of a soluble powder intended for solution, which can be
20 adjusted to neutral pH and isotonic.

The preferred methods of administration of the Formula I compounds include oral and parenteral, e.g., i.v. infusion, i.v. bolus and i.m. injection.

For adults, about 0.5-50 mg of the compound per kg of body weight given one to four times daily is preferred. The
25 preferred dosage is 2.5 mg to 1000 mg of the compound given one to four times per day. More specifically, for mild infections a dose of about 2.5 to 100 mg administered two or three times daily is recommended. For moderate infections against highly susceptible
30 organisms a dose of about 500 mg three or four times daily is recommended. For severe, life-threatening infections against organisms at the upper limits of sensitivity to the compound, a dose of about 1000-2000 mg three to four times daily may be recommended.

- 19 -

For the treatment of vaginal candidiasis, the compound may be administered in a predetermined amount which is not necessarily adjusted for body weight, e.g., 50 mg given once daily for seven to ten days. Typically compounds used for the treatment
5 of vaginal candidiasis will be formulated in a cream or suppository form which is administered intravaginally.


For the treatment of *Pneumocystis carinii* pneumonia, the compound may preferably be administered via the pulmonary route, such as through the use of an intermittent positive pressure
10 breathing (IPPB) apparatus, or in the form of an aerosol or unit dose spray powder. Typically the compound is administered three or four times daily, in an amount sufficient to treat the infection which has developed, or to prevent the development of infection.

As used herein, prevention of a *Pneumocystis* infection
15 in an immunocompromised mammalian patient involves administering a compound in accordance with formula I to the patient prior to the development of symptoms, based upon an expectation that the immunocompromised patient is more likely to develop a *Pneumocystis* infection than an immune competent patient.
20 Immunocompromised patients are readily recognized by the skilled artisan by reviewing the overall condition of the patient, taking into account blood chemistry and cellular component values, e.g., the CD4 lymphocyte count.

The invention is further illustrated in connection with
25 the following non-limiting examples.

30

- 20 -


PREPARATIVE EXAMPLE I

The starting material for Example 1 below is obtained in accordance with the procedures set forth in USSN 901,720 filed on June 15, 1992, and in Balkovec, et al. Tetrahedron Letters, Vol. 33 pages 4529 - 4532 (1992) (identified as Compound 6d). Briefly, compound PE-1 is combined with trifluoroacetic acid. Sodium cyanoborohydride is added and the solution is stirred at room temperature. The volatiles are removed in vacuo to produce a solid, which is purified by reverse phase

- 21 -

HPLC, eluting with water:acetonitrile (45/55) to obtain compound PE-2 as a white solid after lyophilization.

5

PREPARATIVE EXAMPLE II

- 22 -

4-(4-*n*-Pentoxyphenyl)bromobenzene

To a stirred solution of 4-(4-bromophenyl)phenol (25.5 g, 0.102 mol) in 400 mL of dimethylsulfoxide was added 2.5N NaOH (40.9 mL, 0.102 mol) followed by *n*-pentyl bromide (12.7 mL, 0.102 mol). The resulting mixture was heated at 70°C for a period of 18h. After cooling, the yellow solution was partitioned between ethyl acetate (1000 mL) and water (500 mL). The organic phase was washed with water (3X) and brine and dried with magnesium sulfate. The solvent was removed *in vacuo* to give 4-(4-*n*-pentoxyphenyl)bromobenzene (30.9 g).

¹H NMR (400MHz, DMSO-*d*₆) δ 0.93 (t, J=7.2 Hz, 3H), 1.41 (m, 4H), 1.79 (m, 2H), 3.97 (t, J=6.6 Hz, 2H), 6.94 (d, J=8.8 Hz, 2H), 7.39 (d, J=8.6 Hz, 2H), 7.45 (d, J=8.8 Hz, 2H), 7.51 (d, J=8.6 Hz, 2H).

4-(4-*n*-Pentoxyphenyl)phenylboronic acid

To a stirred suspension of 4-(4-*n*-pentoxyphenyl)bromobenzene (1.0 g, 3.13 mmol) in anhydrous tetrahydrofuran (20 mL) at -78°C under a nitrogen atmosphere was added *n*-butyllithium in hexanes (2.5M, 1.32 mL, 3.30 mmol). After a period of 15 min, triisopropylborate (760 mL, 3.30 mmol) was added. Stirring at -78°C was continued for 15 min and then at 25°C for 40 min. The mixture was acidified with 0.5N HCl (20 mL) and then partitioned between ether (50 mL) and water (40 mL). The organic phase was washed with water (3X) and brine and dried with magnesium sulfate. The solvent was removed *in vacuo* to give 4-(4-*n*-pentoxyphenyl)phenylboronic acid (750 mg) as a white solid.

¹H NMR (400MHz, DMSO-*d*₆) δ 0.89 (t, J=7.2 Hz, 3H), 1.38 (m, 4H), 1.72 (m, 2H), 3.99 (t, J=6.5 Hz, 2H), 6.99 (d, J=8.8 Hz, 2H), 7.57 (d, J=8.2 Hz, 2H), 7.60 (d, J=8.8 Hz, 2H), 7.83 (d, J=8.2 Hz, 2H).

4-(*n*-pentyloxyphenyl)-4'-methoxycarbonylbiphenyl

To a stirred solution of 4-(4-*n*-pentyloxyphenyl)phenylboronic acid (1.45 g, 5.11 mmol) and methyl 4-

- 23 -

bromobenzoate (1.21 g, 5.62 mmol) in dimethylformamide (12 mL) was added triethylamine (1.43 mL, 10.21 mmol) followed by triphenylphosphine (536 mg, 2.04 mmol) and palladium(II) acetate (230 mg, 1.02 mmol). The reaction was heated at 80°C for a period of 18h.

5 The cooled mixture was partitioned between methylene chloride and water. The organic phase was washed with 1M sodium bicarbonate, water (2X) and brine, dried over magnesium sulfate and filtered through a bed of celite. The solvent was removed *in vacuo* to give crude product which was purified by pre-adsorption flash silica gel chromatography to provide 4-(n-pentyloxyphenyl)-4'-methoxycarbonylbiphenyl (220 mg).

¹H NMR (400MHz; CDCl₃) δ 0.93 (t, J=7.1 Hz, 3H), 1.41 (m, 4H), 1.83 (m, 2H), 3.93 (s, 3H), 3.99 (t, J=6.6 Hz, 2H), 6.97 (d, J=8.8 Hz, 2H), 8.10 (d, J=8.5 Hz, 2H).

15 MS (EI) = 374

4-(n-pentyloxyphenyl)-4'-carboxybiphenyl

A mixture of 4-(n-pentyloxyphenyl)-4'-methoxycarbonylbiphenyl (220 mg, 0.58 mmol) and 5N sodium hydroxide (1.17 mL, 5.88 mmol) in tetrahydrofuran (20 mL) was heated at 80°C under reflux for a period of 18h. The cooled mixture was acidified with 1N hydrochloric acid (35 mL) and partitioned between ethyl acetate and water. The organic suspension was washed with water (3X) and brine. The organic layer was then filtered to give the carboxylic acid, 4-(n-pentyloxyphenyl)-4'-carboxybiphenyl (210 mg).

25 ¹H NMR (400MHz; DMSO-*d*₆) δ 0.90 (t, J=7.1 Hz, 3H), 1.37 (m, 4H), 1.73 (m, 2H), 4.0 (t, J=6.6 Hz, 2H), 7.02 (d, J=8.9 Hz, 2H), 8.02 (d, J=8.5 Hz, 2H).

MS (EI) = 360.2

Acylation of the Echinocandin B Nucleus

30 The carboxylic acid as prepared above (572 mg) was dissolved in 15 mL of dry N,N-dimethylformamide. Pentafluorophenol (586 mg) and dicyclohexylcarbodiimide (492 mg) were added and the mixture was stirred overnight. Echinocandin B nucleus (846 mg), 5

- 24 -

mL of N,N-dimethylformamide used as a rinse and diisopropyl-ethylamine (0.41 mL) were added. The mixture was stirred for 18 hours at which time it was diluted with water and acetonitrile.

Purification by preparative HPLC (DELTA PAK C18, gradient: 40% CH₃CN / 60% H₂O to 55% CH₃CN / 45% H₂O, λ = 210, 277 nm) gave PE-4 (610 mg) as a solid.

FAB MS (M + Na⁺) 1162.


10

EXAMPLE I

15

20

25



A solution of compound PE-2 (50mg, 0.05mmol) from Preparative Example 1 and sodium iodide (7.5 mg, 0.05 mmol) in methanol was cooled to 0°C. Aqueous sodium hypochlorite (5.25% w/v, 0.0709 mL, 0.05 mmol) was then added dropwise. The resulting yellow solution was allowed to stir at 0°C for 20 minutes. Analytical HPLC (50% CH₃CN / 50% H₂O, 2 mL/min, C8 ZORBAX, 4.6 x 250 mm, λ = 210, 277 nm) indicated complete consumption of starting material. The reaction mixture was treated with 1 mL of 10% aqueous sodium thiosulfate and the pH was adjusted to 7 with 2N HCl. The

- 25 -

resulting solution was diluted to about 5 mL with water, filtered, and injected onto a preparative HPLC column (C8 ZORBAX, 50% CH₃CN / 50% H₂O, λ = 210, 277 nm). Lyophilization of the appropriate fractions as determined by analytical HPLC gave 23 mg of of
5 Compound Ex-1 as a white solid.

Partial ¹H NMR (400 MHz, CD₃OD): δ 7.57 (s, 1H), 7.04 (dd, 1H), 6.75 (dd, 1H), 5.09 (d, 1H), 2.99 (dd, 1H).

FAB MS (M+1): 1158.


10

EXAMPLE II

15

20

25



Part A. Allylation

To a solution of Compound Ex-1 (100 mg, 0.086 mmol) in
30 1-methyl-2-pyrrolidinone (1 mL) was added
tetrakis(triphenylphosphine) palladium(0) (10 mg, 0.009 mmol)
followed by allyltributyltin (0.040 mL, 0.13 mmol). Lithium chloride
(7 mg, 0.17 mmol) was then added and the resulting pale yellow
solution was stirred at 60°C for 2 hours. Analytical HPLC (C8
ZORBAX, 45% H₂O / 55% CH₃CN, λ = 210, 277 nm) showed

- 26 -

conversion of starting material to product. The reaction mixture was diluted with water to about 5 mL, filtered and injected onto a preparative HPLC column (C8 ZORBAX, 50% CH₃CN / 50% H₂O, λ = 210, 277 nm). The appropriate fractions as determined by analytical HPLC were combined and lyophilized to give 54 mg of the ortho-allylated phenol (Compound I-c, R⁸ = -CH₂CH=CH₂) as a white solid.

Partial ¹H NMR (400 MHz, CD₃OD): δ 6.91(s, 1H), 6.87(dd, 1H), 6.69(dd, 1H), 5.09(d, 1H), 2.99(dd, 1H).

FAB MS (M+Li): 1080.0.

Part B. Ozonolysis

A solution of the product from part A above, (70 mg, 0.065 mmol) in 3 mL of methanol was added to a saturated solution of ozone in dichloromethane at -78°C (2.5 mL, ~0.04M, 0.098 mmol).

The resulting solution was stirred at -78°C for 15 minutes and was then allowed to warm to room temperature. Methyl sulfide (1 mL, 13 mmol) was added and the reaction mixture was stirred overnight. Analytical HPLC (45% H₂O / 55% CH₃CN, C8 ZORBAX, λ = 210, 277 nm) showed complete reaction. The solution was diluted to about 5 mL with water and injected onto a preparative HPLC column (C8 ZORBAX, 50% CH₃CN / 50% H₂O, λ = 210, 277 nm). Lyophilization of the appropriate fractions as determined by analytical HPLC gave 47 mg of the aldehyde (Compound I-c, R⁸ = -CH₂CH=O) as a white solid.

Partial ¹H NMR (400 MHz, CD₃OD): δ 6.95 (d), 6.90 (dd), 6.69 (dd), 5.09 (d), 4.79 (m), 2.99 (dd, 1H), 2.89 (dd, 1H), 2.79 (dd, 1H).

FAB MS (M+Li): 1082.0.

Part C. Reductive Amination

To a solution of the product from part B above (11.4 mg, 0.01 mmol) in 0.5 mL of methanol was added ammonium acetate (7.7 mg, 0.1 mmol) and sodium cyanoborohydride (1 mg, 0.016 mmol). The resulting mixture was stirred at room temperature overnight. The reaction mixture was then diluted to about 5 mL with water, filtered


- 27 -

and injected onto a preparative HPLC column (C8 ZORBAX, 50% CH₃CN / 50% H₂O / 0.1% TFA, λ = 210, 277 nm). Lyophilization of the appropriate fractions gave 1.2 mg of Compound Ex-2 as a white solid.

Partial ¹H NMR (400 MHz, CD₃OD): δ 6.95 (dd, 1H), 6.89 (s, 1H), 6.75 (dd, 1H), 5.09 (m, 1H), 3.19 (t, 2H), 2.99 (dd, 1H), 2.95 (t, 2H).

FAB MS (M+Li): 1083.2.

EXAMPLE III



To a solution of the product from part B, example II, above (25 mg, 0.023 mmol) in 0.5 mL of pyridine was added hydroxylamine hydrochloride (5 mg, 0.072 mmol). The resulting solution was stirred at room temperature for 2 hours. Analytical HPLC (45% H₂O / 55% CH₃CN, C8 ZORBAX, λ = 210, 277 nm) showed complete conversion of starting material to one product. The reaction mixture was concentrated by rotary evaporation, diluted with 5 mL of 1:1 CH₃CN/H₂O, filtered, and injected onto a

- 28 -

preparative HPLC column (50% H₂O / 50% CH₃CN, C8 ZORBAX, λ = 210, 277 nm). Lyophilization of the appropriate fractions as determined by analytical HPLC gave 15.8 mg of Compound Ex-3 as a mixture of geometric isomers.

5

Partial ¹H NMR of mixture (400 MHz, CD₃OD):
δ 6.92, 6.91 (dd), 6.90 (s, 1H), 6.74, 6.71 (dd, 1H), 5.09 (d, 1H),
3.61 (d, 2H), 3.41 (d, 2H), 2.99 (dd, 1H).
FAB MS (M+Li): 1097.0.


10

EXAMPLE IV

15

20

25



30

Compound PE-2 from Preparative Example 1 (309 mg, 0.299 mmol) was dissolved in 4 mL of absolute ethanol. Iron (III) nitrate nonahydrate (97 mg, 0.240 mmol) was added and the resultant solution was heated to 60°C. After 12 h of stirring, the mixture was cooled and the volatiles were removed by rotary evaporation at reduced pressure. The residue was dissolved in 55% aqueous acetonitrile and filtered. Purification by preparative reverse phase HPLC (C8


- 29 -

ZORBAX, 45% H₂O / 55% CH₃CN, λ = 210, 277 nm) gave 148 mg of Compound Ex-4 after lyophilization of the appropriate fractions.

Partial ¹H NMR (400 MHz, CD₃OD): δ 7.94 (d, 1H), 7.49 (dd, 1H), 7.08 (d, 1H), 5.11 (d, 1H), 4.98 (d, 1H), 2.99 (dd, 1H), 1.17 (d, 3H).

FAB MS (M+Li): 1083.

EXAMPLE V



10% Palladium on charcoal was suspended in 1 mL of deionized water and sodium borohydride (10.5 mg, 0.279 mmol) was added. After stirring for 1 min, a solution of Compound Ex-4 (150 mg, 0.139 mmol) in 4 mL of methanol was added dropwise. The yellow color of the solution persisted after several minutes therefore approximately 5 mg of sodium borohydride was added. Stirring was continued for 15 min. The reaction was centrifuged to remove the catalyst and the clear solution was filtered through a 0.2 micron filter frit. The solution was kept under nitrogen. The volume was reduced

- 30 -

by passing a stream of dry nitrogen over the solution. The mixture was purified by preparative HPLC (C8 ZORBAX, 50% H₂O / 50% CH₃CN, λ = 210, 277 nm). Lyophilization of the appropriate fractions gave 105

5 Partial ¹H NMR (400 MHz, CD₃OD): δ 6.59 (m, 2H), 6.41 (dd, 1H), 5.09 (d, 1H), 4.97 (d, 1H), 2.99 (dd, 1H), 1.18 (d, 3H).

FAB MS (M+Li): 1053.


10

EXAMPLE VI

15

20

25



30

Compound Ex-5 (20 mg, 0.019 mmol) was dissolved in 0.1N hydrochloric under an atmosphere of nitrogen. The solution was cooled to 0°C and a solution of 1N sodium nitrite (0.0209 mL, 0.0209 mmol) was added. After stirring for 15 minutes, a solution of 1N potassium azide (0.038 mL, 0.038 mmol) was added and the reaction was stirred an additional 15 minutes. The acidity of the solution was adjusted to approximately pH 5 by the addition of 0.2 mL of 1N sodium

- 31 -

acetate and the vessel was removed from the ice bath and stirred for 1 h to give an orange heterogeneous mixture. The solid was removed by filtration and after washing with water was dissolved in methanol. The methanol was removed by rotary evaporation at reduced pressure to give a dark semi-solid. Purification by preparative HPLC (50% H₂O / 50% CH₃CN, C8 ZORBAX, λ = 210, 277 nm) and lyophilization of the appropriate fractions gave 12 mg of Compound Ex-6 as a white solid.


Partial ¹H NMR (300 MHz, CD₃OD): δ 6.89 (d, 1H), 6.86 (s, 1H), 6.77 (d, 2H), 5.14 (d, 1H), 5.02 (m, 1H), 3.02 (dd, 1H), 1.21 (d, 3H).

FAB MS (M+Li-N₂): 1051.

IR (KBr): 2115 cm⁻¹

UV (aqueous CH₃CN): λ_{max} (nm) = 200, 250, 296.

EXAMPLE VII



To a stirred solution of pneumocandin B₀ (0.496 g, 0.466 mmol) in 15 mL of glacial acetic acid was added 1N NaNO₂ (1.0 mL,


- 32 -

0.001 mol). After stirring at room temperature for 18h the solvent was removed by rotary evaporation to yield an orange semi-solid. The crude product was dissolved in a minimal amount of aqueous methanol, filtered and purified by preparative reverse phase HPLC (C8 ZORBAX, 55% water/45% acetonitrile, $\lambda = 210, 277$ nm). The appropriate fractions were combined, frozen and lyophilized to give 0.235 g of Compound Ex-7 as a yellow amorphous solid.

Partial ^1H NMR (400 MHz, CD_3OD): δ 8.01 (d, 1H), 7.69 (dd, 1H), 7.14 (d, 1H), 5.28 (d, 1H), 5.09 (d, 1H), 4.98 (d, 1H), 1.15 (d, 3H).

FAB MS ($\text{M}+\text{Li}$): 1116.

EXAMPLE VIII



Compound Ex-7 (0.126 g, 0.114 mmol) was dissolved in 4 mL of methanol. After flushing the reaction vessel with N_2 , 35 mg of 10% Pd on charcoal was added followed by 1 mL of distilled water. Sodium borohydride (8.6 mg, 0.227 mmol) was added to the reaction


- 33 -

mixture in 2 portions over 5 min. Approximately 0.3 mL acetic acid was cautiously added to the heterogeneous mixture. After stirring for 1 h, the reaction was filtered through a 0.2 micron filter. The crude product was purified by preparative reverse phase HPLC (C8 ZORBAX, 50% water/50% acetonitrile, $\lambda = 210, 277$ nm). The appropriate fractions were combined, frozen and lyophilized to give 0.081 g of Compound Ex-8 as an off-white amorphous solid.

Partial ^1H NMR (400 MHz, CD_3OD): δ 6.73 (d, 1H), 6.64 (d, 1H), 6.51 (dd, 1H), 5.28 (d, 1H), 5.09 (m, 1H), 4.98 (d, 1H), 1.18 (d, 3H).

FAB MS (M+Li): 1086.

EXAMPLE IX



- 34 -

Part A. Conjugation

Compound Ex-8 (68 mg, 0.063 mmol) and pentafluorophenyl N-benzyloxycarbonylglycinate (35 mg, 0.0944 mmol) were dissolved in 0.5 mL of N-methylpyrrolidinone. The mixture was stirred for 24 h at room temperature. Purification was accomplished by preparative HPLC (C8 ZORBAX, 55% water/45% acetonitrile, $\lambda = 210, 277$ nm). The appropriate fractions were combined, frozen and lyophilized to give 40 mg of the N-protected glycyl conjugate (Compound I-a, $R^8 =$

10 -NH(C=O)CH₂NH(C=O)OCH₂C₆H₅) as an amorphous solid.

FAB MS (M+Li): 1278.

Part B. Hydrogenolysis

The product from Part A above (40 mg, 0.031 mmol) was dissolved in 2 mL of glacial acetic acid. Next, 2 mL of deionized water was added followed by 20 mg of 10% palladium on charcoal. The vessel was flushed with hydrogen gas and stirring under one atmosphere of hydrogen was continued for 2 h. The catalyst was removed by filtration and the volatiles were removed by rotary evaporation under reduced pressure. The residue was dissolved in a small volume of water, frozen and lyophilized to give 35 mg of Compound Ex-9 as an amorphous solid.

15

20


Partial ¹H NMR (400 MHz, CD₃OD): δ 7.92 (d, 1H), 6.97 (dd, 1H), 6.84 (d, 1H), 5.28 (d, 1H), 5.08 (m, 1H), 4.97 (d, 1H), 1.18 (d, 3H).

25

FAB MS (M+Li): 1143.8.

30

- 35 -

EXAMPLE X**Part A. Etherification**

The adduct from Part A Example IX above (400 mg, 0.315 mmol) was dissolved in 40 mL of p-dioxane containing 4 mL of N,N-dimethyl-dimethylformamide. N-Benzyloxycarbonyl-ethanolamine (3.03 g, 15.7 mmol) was added followed by (+)-camphorsulfonic acid (88 mg). Stirring was continued at room temperature for 22 h. The reaction was quenched with approximately 2 mL of saturated sodium hydrogen carbonate solution. The volatiles were removed by concentration at reduced pressure and the mixture purified by preparative HPLC (C18 ZORBAX, 60% water / 40% acetonitrile to 40% water / 60% acetonitrile, $\lambda = 210, 277$ nm). The appropriate fractions were combined, frozen and lyophilized to give 0.30 g of the bis-benzyloxycarbonyl-protected product.

- 36 -


Part B. Hydrogenolysis

The adduct from Part A Example X above (0.30 g, 0.21 mmol) was dissolved in 20 mL of glacial acetic acid. To the flask was added 0.11 g of 10% palladium on charcoal. The vessel was flushed with nitrogen followed by hydrogen gas. The reaction was stirred rapidly under one atmosphere of hydrogen gas for 1.5 h. The catalyst was removed by filtration through a 0.45 micron frit. The catalyst was washed with a small amount of 75% aqueous acetic acid. The filtrate was concentrated to about 6 mL under reduced pressure and purified by preparative reverse phase HPLC (C18 ZORBAX, 60% water / 40% acetonitrile / 0.1% trifluoroacetic acid, $\lambda = 220, 286$ nm). The appropriate fractions were lyophilized and dissolved in 10 mL of 0.5 N hydrochloric acid and lyophilized. The residue was repurified by preparative HPLC (C18 ZORBAX, 60% water / 40% acetonitrile, $\lambda = 220, 286$ nm) and the appropriate fractions lyophilized to yield 95 mg of Compound Ex-10 as a dihydrochloride salt.

Partial ^1H NMR (400 MHz, CD_3OD): δ 7.94 (d, 1H), 6.98 (dd, 1H), 6.84 (d, 1H), 5.27 (d, 1H), 5.10 (m, 1H), 5.01 (d, 1H), 3.12 (t, 2H), 1.16 (d, 3H).

FAB MS ($\text{M}+\text{Li}$): 1186.6.

- 37 -

EXAMPLE XI

20 Part A. Conjugation

Compound Ex-8 (40 mg, 0.037 mmol) and pentafluorophenyl N-benzyloxycarbonyl- β -alaninate (15.2 mg, 0.0390 mmol) were dissolved in 1.0 mL of N,N-dimethylformamide (DMF). The mixture was stirred for 60 h at room temperature. The DMF was removed by rotary evaporation at reduced pressure. Purification of the residue was accomplished by preparative HPLC (C8 ZORBAX, 45% water/55% acetonitrile, $\lambda = 230, 277$ nm). The appropriate fractions were combined, frozen and lyophilized to give 25 mg of the desired conjugate (Compound I-a, $R^8 =$

25

30 -NH(C=O)CH₂CH₂NH(C=O)OCH₂C₆H₅) as an amorphous solid.

FAB MS (M+Li): 1291.


Part B. Hydrogenolysis

The product from Part A Example XI above (23.5 mg, 0.0183 mmol) was dissolved in 1 mL of glacial acetic acid. Next, 20.5

- 38 -

mg of 10% palladium on charcoal. The vessel was flushed with hydrogen gas and stirring under one atmosphere of hydrogen was continued for 3 h. The catalyst was removed by filtration, washed with methanol and the volatiles were removed by rotary evaporation under reduced pressure. The residue was dissolved in a small volume of water, frozen and lyophilized to give 17.8 mg of Compound Ex-11 as an amorphous solid.

FAB MS (M+H): 1152

EXAMPLE XII

Compound Ex-11 (31 mg, 0.026 mmol) was dissolved in 0.4 mL of dry N,N-dimethylformamide. Ethyl acetamidate hydrochloride (4.7 mg, 0.038 mmol) was added followed by pyridine (0.0031 mL, 0.0384 mmol). The mixture was stirred at room temperature for 72 h, then, the volatiles were removed under


- 39 -

reduced pressure. The residue was purified by preparative reverse phase HPLC (C8 ZORBAX, 50% water / 50% acetonitrile/ 0.1% trifluoroacetic acid, $\lambda = 230, 277$ nm). The appropriate fractions were combined, frozen and lyophilized to give 14.5 mg of
5 Compound Ex-12 as an amorphous solid.


Partial ^1H NMR (400 MHz, CD_3OD): δ 7.76 (d, 1H), 6.97 (dd, 1H), 6.84 (d, 1H), 5.28 (d, 1H), 5.08 (m, 1H), 4.98 (d, 1H), 3.60 (m, 2H), 1.17 (d, 3H).

FAB MS (M+Li): 1198.8.

EXAMPLE XIII



- 40 -




The starting bis-amine compound is obtained in accordance with J. Med. Chem. 37: 222-225 (1994) (identified as Compound 9) and used as its dihydrochloride salt. The compound (80 mg, 0.069 mmol) was dissolved in 1.0 mL of glacial acetic acid. A 1M solution of sodium nitrite (0.288 mL, 0.288 mmol) was added and the reaction was stirred for 48 h at ambient temperature. The yellow-orange reaction mixture was diluted with approximately 5 mL of water and purified by preparative reverse phase HPLC (C18 ZORBAX, 65% water/35% acetonitrile/0.1% trifluoroacetic acid, $\lambda = 210, 277$ nm). The appropriate fractions were combined, frozen and lyophilized to give 36 mg of Compound Ex-13 as a pale yellow amorphous solid.

Partial ^1H NMR (400 MHz, CD_3OD): 87.99 (d, 1H), 7.59 (dd, 1H), 7.15 (d, 1H), 5.18 (d, 1H), 4.98 (m, 1H), 3.13 (t, 2H), 3.06 (m, 2H), 1.17 (d, 3H).

ESI MS ($\text{M}+\text{H}$): 1139.

- 41 -

EXAMPLE XIV

20 Compound Ex-13 (31.5 mg, 0.023 mmol) was dissolved in 1.0 mL of methanol. Distilled water (0.25 mL) was added. The reaction vessel was flushed with nitrogen and 10 mg of 10% Pd on charcoal was suspended in the pale yellow solution. Sodium borohydride (4.8 mg, 0.127 mmol) was added in two portions over 5 minutes. The mixture was stirred for 30 min and quenched by the

25 addition of several drops of glacial acetic acid. The Pd-C was removed by filtration through a 0.2 micron frit and the solution was diluted with several mLs of water. The desired product was purified by preparative reverse phase HPLC (Rx C18 ZORBAX, 65% water/35%

30 acetonitrile/0.1% TFA, $\lambda = 210, 277$ nm). The appropriate fractions were combined, frozen and lyophilized to give 26 mg of Compound Ex-14 as a white amorphous solid.

Partial ^1H NMR (400 MHz, CD_3OD): δ 6.95 (bs, 1H), 6.78 (m, 2H), 5.17 (d, 1H), 4.98 (d, 1H), 3.13 (t, 2H), 3.07 (t, 2H), 1.17 (d, 3H).

- 42 -

UV spectrum (acetonitrile/water/0.1% TFA): λ_{\max} (nm) = 205, 222(s), 274.

ESI MS (M+H): 1109.


5

EXAMPLE XV

10

15

20



Compound Ex-14 above (23 mg, 0.017 mmol) was dissolved in 1.0 mL of glacial acetic acid. A 1N sodium nitrite solution (0.104 mL, 0.104 mmol) was added. The mixture was stirred for 10 min and a 0.5M sodium azide solution (0.412 mL, 0.206 mmol) was added. Stirring was continued at room temperature for 1 h. The mixture was purified by preparative reverse phase HPLC (Rx C18 ZORBAX, 70% water / 30% acetonitrile/0.1% TFA to 60% water / 40% acetonitrile/0.1% TFA, λ = 210, 277 nm). The appropriate fractions were combined, frozen and lyophilized in the dark to give 13 mg of Compound Ex-15 as a white amorphous solid.


- 43 -

Partial ^1H NMR (400 MHz, CD_3OD): δ 6.92 (m, 2H), 6.79 (d, 1H), 5.18 (d, 1H), 4.98 (d, 1H), 3.13 (t, 2H), 3.07 (t, 2H), 1.17 (d, 3H).

UV spectrum (acetonitrile/water/0.1% TFA): λ_{max} (nm) = 205, 250, 295.

ESI MS ($\text{M}+\text{H}$): 1135.

EXAMPLE XVI



A suspension of pneumocandin B₀ (0.200 g, 0.188 mmol) in 15 mL of glacial acetic acid was heated gently to effect complete dissolution. A 5.25% aqueous w/v solution of sodium hypochlorite (0.268 mL, 0.188 mmol) was added. After stirring for 15 min, the solution was frozen and lyophilized to give 232 mg of the crude product. Partial purification of the residue was accomplished by flash reverse phase chromatography (40% CH_3CN / 60% H_2O , then 50% CH_3CN / 50% H_2O ; LICHROPREP RP-18 [40-63 micron]). Lyophilization of the appropriate fractions gave 102 mg of material for purification by preparative reverse phase HPLC

- 44 -


(50% CH₃CN / H₂O, C8 ZORBAX, λ = 270 nm). Lyophilization of the appropriate fractions gave 62 mg of Compound Ex-16.

IR (Nujol) cm⁻¹: 3340 (br), 1720 (br), 1640 (br)

FAB MS (M+Li): 1105.

5

EXAMPLE XVII



(C-5 *orn*, C-4 *htyr*)-dideoxytetrahydroechinocandin B
obtained in accordance with USSN 901,720 filed on June 15, 1992,
25 and in Balkovec, et al. Tetrahedron Letters, Vol. 33, pp. 4529 - 4532
(1992) (identified as compound 2d) (18 mg, 0.0174 mmol) and
tetranitromethane (0.0031 mL, 0.0262 mmol) were dissolved in 0.5
mL of absolute ethanol. N,N-4-Dimethylaminopyridine
30 (approximately 3 mg) was added and the reaction mixture was
stirred at room temperature for 24 h. The volatiles were removed
under reduced pressure to obtain a yellow residue. The residue was
purified by preparative reverse phase HPLC (30% H₂O / 70%
CH₃CN, C8 ZORBAX, λ = 210, 277 nm) and lyophilization of the

- 45 -

appropriate fractions gave 4.5 mg of pure nitro adduct and 3.1 mg of Compound Ex-17.

Partial ^1H NMR (400 MHz, CD_3OD): δ 7.95 (d, 1H), 7.50 (dd, 1H), 7.08 (d, 1H), 4.97 (d, 1H), 4.33 (d, 1H), 2.96 (dd, 1H).

5


FAB MS ($\text{M}+\text{H}$): 1077.

EXAMPLE XVIII

10

15

20



25

Compound Ex-17 (13 mg, 0.012 mmol) was dissolved in 1 mL of absolute ethanol. 10% palladium on charcoal (10 mg) was added and the reaction was flushed with hydrogen gas. After rapid stirring for 4 h under an atmosphere of hydrogen gas, the reaction mixture was filtered through a 0.2 micron frit. The filtrate was concentrated under reduced pressure to provide a white solid residue. Purification by reverse phase HPLC (30% H_2O / 70% CH_3CN , C8 ZORBAX, $\lambda = 210, 277 \text{ nm}$) and lyophilization of the appropriate fractions gave 8 mg of Compound Ex-18.

30

Partial ^1H NMR (400 MHz, CD_3OD): δ 6.61 (m, 2H), 6.42 (dd, 1H), 2.96 (dd, 1H).

- 46 -

FAB MS (M+H): 1047.


EXAMPLE XIX

5

10


15

20



Pneumocandin D₀ (76 mg, 0.070 mmol) is dissolved in 1.0 mL of glacial acetic acid. A 1M solution of sodium nitrite (0.28 mL, 0.28 mmol) is added and the reaction is stirred for 48 h at ambient temperature. The reaction mixture is diluted with approximately 5 mL of water and purified by preparative reverse phase HPLC (C18 ZORBAX, 65% water/35% acetonitrile/0.1% trifluoroacetic acid, λ = 210, 277 nm). The appropriate fractions are combined, frozen and lyophilized to give Compound Ex-19 with a molecular weight of 1126.3.


- 47 -

EXAMPLE XX

Pneumocandin A₀ (108 mg, 0.1 mmol) is dissolved in 10 mL glacial acetic acid. Aqueous 1M sodium hypobromite (0.1 mL, 0.1 mmol) is added dropwise at room temperature and the mixture is stirred for enough time to consume most of the pneumocandin A₀. The mixture is diluted with water and purified by reverse phase HPLC (C18 ZORBAX, 50% H₂O / 50% CH₃CN, λ = 210, 277 nm). Lyophilization of the appropriate fractions as determined by analytical HPLC give Compound Ex-20 with a molecular weight of 1158.2.

30

- 48 -


EXAMPLE XXI

20 Compound PE-4 (0.1 mmol) and sodium iodide (0.1 mmol) are dissolved in 10 mL of methanol. The solution is cooled to 0°C and aqueous sodium hypochlorite (5.25% w/v, 0.1 mmol) is added dropwise. The resultant solution is stirred at 0°C until the majority of starting lipopeptide is consumed as determined by analytical HPLC

25 (50% CH₃CN / 50% H₂O, C18 ZORBAX, λ = 210 nm). The reaction mixture is treated with a sufficient amount of 10% aqueous sodium thiosulfate to quench any excess iodinating reagent and the pH is adjusted to 7 with 2N HCl. The resulting mixture is diluted with water, filtered, and purified by reverse phase HPLC (C18 ZORBAX, 50% H₂O

30 / 50% CH₃CN, λ = 210 nm). Lyophilization of the appropriate fractions as determined by analytical HPLC give Compound Ex-21 with a molecular weight of 1266.16.

- 49 -

EXAMPLE XXII

20 Part A. Palladium Coupling

To a solution of Compound Ex-21 (0.1 mmol) in 1-methyl-2-pyrrolidinone (10 mL) is added tetrakis-(triphenylphosphine)palladium(0) (0.010 mmol) followed by tetra(3-butenyl)tin (0.15 mmol). Lithium chloride (0.017 mmol) is then added

25 and the mixture is stirred at 60°C until analytical HPLC (C18 ZORBAX, 35% H₂O / 65% CH₃CN, λ = 210 nm) shows conversion of starting material to a product. The reaction mixture is diluted with water, filtered and injected onto a preparative HPLC column (C18 ZORBAX, 50% H₂O / 50% CH₃CN, λ = 210 nm). The appropriate

30 fractions as determined by analytical HPLC are combined and lyophilized to give the homoallyl adduct (R⁸ = -CH₂CH₂CH=CH₂) of molecular weight 1194.36.

- 50 -


Part B. Ozonolysis

A solution of the product from part A above, (0.1 mmol) in 5 mL of methanol is added to a saturated solution of ozone in dichloromethane at -78°C (2.5 mL, ~0.04M, 0.1 mmol). The resultant solution is stirred at -78°C for 15 minutes and is then allowed to warm to room temperature. Methyl sulfide (1 mL, 13 mmol) is added and the reaction mixture is stirred overnight. The solution is diluted with water and purified by preparative HPLC (C18 ZORBAX, 45% CH₃CN / 55% H₂O, λ = 210 nm). Lyophilization of the appropriate fractions as determined by analytical HPLC (35% H₂O / 65% CH₃CN, C18 ZORBAX, λ = 210 nm) gives the aldehyde (R⁸ = -CH₂CH₂CH=O) with a molecular weight of 1196.33.

Part C. Reductive Amination

To a solution of the product from part B above (0.01 mmol) in 0.5 mL of methanol is added dimethylammonium acetate (0.1 mmol) and sodium cyanoborohydride (0.016 mmol). The resultant mixture is stirred at room temperature overnight. The reaction mixture is then diluted to about 5 mL with water, filtered and injected onto a preparative HPLC column (Rx C18 ZORBAX, 50% CH₃CN / 50% H₂O / 0.1% TFA, λ = 210 nm). Lyophilization of the appropriate fractions gives Compound Ex-22 with a molecular weight of 1139.44.


- 51 -

EXAMPLE XXIII

20 To a solution of the product from part B, example
XXII, above (0.05 mmol) in 1.0 mL of pyridine is added
hydroxylamine hydrochloride (0.1 mmol). The resultant solution is
stirred at room temperature for 2 hours. The reaction mixture is
concentrated by rotary evaporation, diluted with 1:1 CH₃CN/H₂O,
25 filtered, and purified by preparative HPLC (45% H₂O / 55%
CH₃CN, C18 ZORBAX, λ = 210 nm). Lyophilization of the
appropriate fractions as determined by analytical HPLC (40% H₂O /
60% CH₃CN, C18 ZORBAX, λ = 210 nm) gives Compound Ex-23
with a molecular weight of 1211.34.

30

- 52 -

EXAMPLES XXIV-XXVIII




20 In a manner similar to Example VII above, the following nitro compounds represented by the above structure are prepared, varying the nature of the group R^I . The starting hexapeptides may be prepared in accordance with the general procedure for the N-acylation of the A30912A cyclohexapeptide nucleus found in EP 0561639-A1 published on September 22, 1993, modified to include an appropriate

25 activated ester in place of a 2, 4, 5-trichlorophenyl ester. Appropriate activated esters for acylation of the nucleus are precisely described in EP 0486011-A2 published on May 20, 1992.

30

<u>Example</u>	<u>R^I</u>	<u>Sequence ID</u>
XXIV		SEQ ID NO. 36
XXV		SEQ ID NO. 37

- 53 -

XXVI		SEQ ID NO. 38
XXVII		SEQ ID NO. 39
XXVIII		SEQ ID NO. 40

- 54 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: BALKOVEC, JAMES M
BLACK, REGINA M
BOUFFARD, FRANCES A
- (ii) TITLE OF INVENTION: ANTIFUNGAL AND ANTI-PNEUMOCYSTIS
COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND
METHODS OF USE
- (iii) NUMBER OF SEQUENCES: 40
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: ELLIOTT KORSEN
 - (B) STREET: P.O. BOX 2000, 126 E. LINCOLN AVENUE
 - (C) CITY: RAHWAY
 - (D) STATE: NJ
 - (E) COUNTRY: US
 - (F) ZIP: 07065
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/222,157
 - (B) FILING DATE: 04-APR-1994
 - (C) CLASSIFICATION: 514
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: KORSEN, ELLIOTT
 - (B) REGISTRATION NUMBER: 32,705
 - (C) REFERENCE/DOCKET NUMBER: 18956
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 908-594-5493
 - (B) TELEFAX: 908-594-4720

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

- 55 -

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Xaa Xaa Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

- 56 -

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:8:

- 57 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown

- 58 -

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

- 59 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

- 60 -

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids

- 61 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

- 62 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

- 63 -

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid

- 64 -

(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

- 65 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Xaa Thr Xaa Xaa Thr Xaa
1 5

- 66 -

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Xaa Thr Xaa Xaa Thr Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide


(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Xaa Thr Xaa Xaa Thr Xaa
1 5

- 67 -

WHAT IS CLAIMED IS:

1. A compound represented by the formula I:




- 20 or a pharmaceutically acceptable salt or hydrate thereof wherein:
 R^1 represents C9 to C19 alkyl, C9 to C19 alkenyl, aryl selected from the group consisting of: phenyl, biphenyl, naphthyl and terphenyl; or a C1 to C12 alkyl, alkylamino, dialkylamino or alkoxyaryl group;
 R^1 , R^2 and R^4 independently represent H or -OH;
 25 R^3 represents H, -OH, $-O(CH_2)_nNR^VR^{VI}$, where R^V and R^{VI} independently represent H or C1-4 alkyl, or $-O(CH_2)_nNR^VR^{VI}R^{VII}+Y^-$, wherein R^V and R^{VI} are as defined above, R^{VII} represents H or C1-4 alkyl, n is an integer of from 2-6 inclusive, and Y represents a counterion;
 30 R^5 represents H, -CH₃ or -OH;
 R^6 represents H or -CH₃;
 R^7 represents H, -CH₃, $-CH_2C(=O)NH_2$, $-(CH_2)_2NR^VR^{VI}$ or $-(CH_2)_2NR^VR^{VI}R^{VII}+Y^-$ with n, R^V , R^{VI} , R^{VII} and Y as defined above;

- 68 -

and R^8 represents -Cl, -Br, -I, -NO₂, -N₃, -(CH₂)₀₋₄NR^VR^{VI} wherein R^V and R^{VI} are as previously defined, -(CH₂)₀₋₃CH(=NOH), -NHC(=O)(CH₂)₁₋₆NH₂ or -NHC(=O)(CH₂)₁₋₆NHC(=NH)(CH₂)₀₋₃H.


- 5 2. A compound in accordance with claim 1 represented by the structural formula:



- 25 wherein R^8 represents a member selected from the group consisting of -Cl, -I, -NO₂, -NH₂, -N₃, -NHC(O)CH₂NH₂, -NHC(O)CH₂CH₂NH₂ and -NHC(O)CH₂CH₂N(C=NH)CH₃.

- 30 3. A compound in accordance with claim 1 represented by the structural formula:


- 69 -



wherein R⁸ represents NH₂ or NO₂.

4. A compound in accordance with claim 1 represented by the structural formula:


20



- 70 -

wherein R^8 represents I, NO_2 , NH_2 , $-N_3$, $-CH_2CH(=NOH)$, $-CH_2CH_2NH_2$.


- 5 5. A compound in accordance with claim 1 represented by the structural formula:



- 25 wherein R^8 is represented by $NH(C=O)CH_2NH_2$

6. A compound in accordance with claim 1 represented by the structural formula:
- 30


- 71 -









wherein R⁸ represents -NO₂, -NH₂ or -N₃.

20







7. A compound represented by one of the following structural formulas:






- 72 -



- 73 -





- 74 -





30

- 75 -




- 76 -




- 78 -



- 5 8. A compound represented by the formula:



wherein the value of R^I is selected from the group consisting of:



- 77 -



- 79 -

9. A pharmaceutical composition comprised of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier.

5 10. A method of treating a fungal infection in a mammalian patient in need of such treatment comprising administering a compound in accordance with claim 1 to said patient in an amount effective to treat said fungal infection.

10 11. A method of treating a *Pneumocystis* infection in a mammalian patient in need of such treatment comprising administering a compound in accordance with claim 1 to said patient in an amount effective to treat said *Pneumocystis* infection.

15 12. A method of preventing a *Pneumocystis* infection in an immunocompromised mammalian patient in need of such treatment comprising administering a compound in accordance with claim 1 to said patient in an amount effective to prevent said *Pneumocystis* infection.

20

25

30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/03948

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12P 21/04

US CL : 530/317; 514/11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/317; 514/11

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS Online

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,931,352 (Fromtling et al.) 05 JUNE 1990, column 2 lines 1-23.	1-12

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

02 JUNE 1995

Date of mailing of the international search report

26 JUN 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CATHERINE SCALZO

Telephone No. (703) 308-1235